Imagen de Portada

Minimizing Racial Algorithmic Bias when Predicting Electronic Health Record Data Completeness

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Priyanka Anand, Yinzhu Jin, Jun Liu, Joyce Lii, Shruti Belitkar, Kueiyu Joshua Lin
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Establishing a Validation Framework of Treatment Discontinuation in Claims Data Using Natural Language Processing and Electronic Health Records
por: Chun‐Ting Yang, et al.
Publicado: (2025)

Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof‐of‐Principle Analysis
por: Sushama Kattinakere Sreedhara, et al.
Publicado: (2026)

Information Bias in Electronic Health Records and Administrative Claims Data: A Targeted Review of the Recent Literature
por: Patrick J. Arena, et al.
Publicado: (2025)

Development and Validation of the Pharmacological Statin‐Associated Muscle Symptoms Risk Stratification Score Using Electronic Health Record Data
por: Boguang Sun, et al.
Publicado: (2024)

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data
por: Eissa A. Jafari, et al.
Publicado: (2025)

Patient Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies
por: Ameet Sarpatwari, et al.
Publicado: (2025)

Discovering Severe Adverse Reactions From Pharmacokinetic Drug–Drug Interactions Through Literature Analysis and Electronic Health Record Verification
por: Eugene Jeong, et al.
Publicado: (2024)

Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation
por: Matthew M. Abernathy, et al.
Publicado: (2024)

Emulating Comparative Oncology Trials With Real‐World Evidence Studies ( ENCORE ): Process Development and Methodological Considerations for Oncology Real‐World Data
por: Janick Weberpals, et al.
Publicado: (2026)

Drug‐Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources
por: Anna Maria Wermund, et al.
Publicado: (2025)

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents
por: Ethan A. Poweleit, et al.
Publicado: (2024)

Dual Minimal Physiologically Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites in Humans
por: Weihua Jiang, et al.
Publicado: (2025)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT ‐ ACS Emulation Using National Health Insurance Claims Data
por: Li‐Wen Huang, et al.
Publicado: (2025)

Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic Outcomes
por: Anu Patel, et al.
Publicado: (2024)

A Hybrid Design Incorporating External Data to Evaluate Dexamethasone Intracameral Drug Delivery Suspension for Post‐Cataract Surgery Inflammation
por: Yuanyuan Zhao, et al.
Publicado: (2025)

Structure‐Based Prediction of QT Prolongation Risk Using Graph Neural Networks: An Integrative Approach Combining In Vitro hERG Assays and Pharmacovigilance Data
por: Tomoyuki Enokiya, et al.
Publicado: (2026)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
por: Gerald Chun‐To So, et al.
Publicado: (2025)

Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders
por: Hyun‐ju Lee, et al.
Publicado: (2025)

Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018–2021: A Qualitative Analysis of Industry‐Sponsored Post‐Authorization Safety Studies
por: Renske J. Grupstra, et al.
Publicado: (2024)

Developing and Refining the Pregnancy Algorithm CErtaInty Tool ( ACE ‐ IT ) for Validating Pregnancy Outcomes
por: Sonal Singh, et al.
Publicado: (2025)

Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
por: Caroline Marra, et al.
Publicado: (2024)

The Promise of Health for All: A Collaborative Model to Close Treatment Gaps for Neglected Diseases
por: Delali Attipoe
Publicado: (2024)

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies
por: Rachel K. Scott, et al.
Publicado: (2026)

Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions
por: Samuel Gerlach, et al.
Publicado: (2024)

Machine Learning for Prediction of Drug Concentrations: Application and Challenges
por: Shuqi Huang, et al.
Publicado: (2025)

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines
por: Katherine Richardson, et al.
Publicado: (2026)

Regulatory Pathways for Qualification and Acceptance of Digital Health Technology‐Derived Clinical Trial Endpoints: Considerations for Sponsors
por: Jessie P. Bakker, et al.
Publicado: (2024)

Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
por: Cheryl Grandinetti, et al.
Publicado: (2025)

Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population‐Based Cohort Study
por: Hyesung Lee, et al.
Publicado: (2025)

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis
por: Dan‐Yang Liu, et al.
Publicado: (2025)

What African Patients, Clinicians, and Regulators Can Gain from Pharmacometrics: Forecasts for the Future in a New Era in Health
por: Steven E. Kern
Publicado: (2025)

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation
por: Moherndran Archary, et al.
Publicado: (2026)

Reframing the “Rescue Window”: From Physiological Upper Bounds to Actionable Thresholds
por: Man Sun, et al.
Publicado: (2026)

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative
por: Joel L. Weissfeld, et al.
Publicado: (2026)

Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling
por: Suwasin Udomkarnjananun, et al.
Publicado: (2024)

Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
por: Robin Thomas Ulrich Haid, et al.
Publicado: (2024)

Methodology for Good Machine Learning with Multi‐Omics Data
por: Thibaud Coroller, et al.
Publicado: (2024)

FRAME: Framework for Real‐World Evidence Assessment to Mitigate Evidence Uncertainties for Efficacy/Effectiveness – An Evaluation of Regulatory and Health Technology Assessment Decision Making
por: Gianmario Candore, et al.
Publicado: (2025)

Algorithmic Identification of Treatment‐Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease
por: Anna L. Silverman, et al.
Publicado: (2024)

Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers
por: Sébastien Benzekry, et al.
Publicado: (2024)